Photo from wikipedia
I READ WITH INTEREST THE STUDY BY PARIKH AND associates evaluating the role of intravitreal bevacizumab (IVB) in vitreous hemorrhage due to proliferative diabetic retinopathy. The results of the study… Click to show full abstract
I READ WITH INTEREST THE STUDY BY PARIKH AND associates evaluating the role of intravitreal bevacizumab (IVB) in vitreous hemorrhage due to proliferative diabetic retinopathy. The results of the study can be clinically more meaningful if the follow-up schedule after IVB is provided. It would be interesting to know the criteria and the time frame for retreatment that was followed in the study. To integrate the results of the study into clinical practice, it is necessary to know the clinical parameters that guided the authors to choose one treatment option over another
Journal Title: American journal of ophthalmology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!